Pregabalin (All indications)

Spina bifida

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10045
R36361
Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Spina bifida 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.79 [0.11;28.70] C
excluded (control group)
1/1,671   1/2,997 2 1,671
ref
S10046
R36384
Blotière (Controls unexposed NOS) (Other indications), 2019 Spina bifida 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.82 [0.26;12.97] C 1/1,671   616/1,875,733 617 1,671
ref
S8534
R28297
Veiby (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Spina bifida throughout pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 28.22 [0.55;1446.94] C
excluded (control group)
0/30   0/833 0 30
ref
S8536
R28305
Veiby (Controls unexposed, sick) (Mixed indications), 2014 Spina bifida throughout pregnancy population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 18.25 [0.92;361.30] C 0/30   3/3,773 3 30
ref
Total 2 studies 4.33 [0.49;38.62] 620 1,701
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Controls unexposed NOS) (Other indications), 2019Blotière, 2019 1 1.82[0.26; 12.97]6171,67162%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Veiby (Controls unexposed, sick) (Mixed indications), 2014Veiby, 2014 2 18.25[0.92; 361.30]33038%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 37% 4.33[0.49; 38.62]6201,7010.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed NOS) (Other indications; 2: Controls unexposed, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 4.33[0.49; 38.62]6201,70137%NABlotière (Controls unexposed NOS) (Other indications), 2019 Veiby (Controls unexposed, sick) (Mixed indications), 2014 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.82[0.26; 12.97]6171,671 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 unexposed, sickunexposed, sick 18.25[0.92; 361.30]330 -NAVeiby (Controls unexposed, sick) (Mixed indications), 2014 1 Tags Adjustment   - No  - No 4.33[0.49; 38.62]6201,70137%NABlotière (Controls unexposed NOS) (Other indications), 2019 Veiby (Controls unexposed, sick) (Mixed indications), 2014 2 Controls   - epilepsy indication  - epilepsy indication 18.25[0.92; 361.30]330 -NAVeiby (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 4.33[0.49; 38.62]6201,70137%NABlotière (Controls unexposed NOS) (Other indications), 2019 Veiby (Controls unexposed, sick) (Mixed indications), 2014 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8534, 10045

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.82[0.26; 12.97]6171,671 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 unexposed, sick controlsunexposed, sick controls Out of scale18.25[0.92; 361.30]330 -NAVeiby (Controls unexposed, sick) (Mixed indications), 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 4.92[0.36; 66.35]21,70121%NABlotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Veiby (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 20.510.01.0